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Abstract
Catecholaminergic polymorphic ventricular tachycardia is a familial cardiac arrhythmia that is 
related to RYR2 or CASQ2 gene mutation. It occurs in patients with structurally normal heart 
and causes exercise-emotion triggered syncope and sudden cardiac death. We present a 13 
year-old girl with recurrent episodes of exercise-related syncope and prior history of sudden 
death  in  a  first  degree  relative.                                      
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A  13-year-old  girl  with  no  cardiovascular  history  presented  for  evaluation  of  recurrent 
episodes  of  exercise-related  syncope  and  prior  history  of  sudden  death  in  a  first  degree 
relative. The 12- lead electrocardiogram (ECG) at rest was normal and an echocardiogram 
confirmed a structurally  normal heart.  A 24-hour Holter monitoring (Figure 1,  left  panel) 
during  physical  activity  showed  the  classic  electrocardiographic  manifestation  of 
catecholaminergic  polymorphic  ventricular  tachycardia  (CPVT):  bidirectional  ventricular 
tachycardia (BVT), two alternating QRS complexes morphologies with different polarity (X 
and Y,  Figure 1 right panel) with an XY interval of 240 ms and YX interval of 280 ms. It  
may be necessary to conduct a 12-lead ECG to confirm if those polarities represented right 
bundle branch block and left bundle branch block respectively. The BVT presented regular X-
X and Y-Y intervals both at 520 ms. According to the classification originally proposed by 
Scherf and Kisch, the BVT presented here is a Type II BVT, defined by a regular and fixed 
alternation of short and long intervals.[1,2]
The patient was treated with propanolol 120 mg/day. During a control exercise stress test the 
patient  presented  again  with  CPVT  symptomatic  by  syncope.  An  implantable  automatic 
cardioverter defibrillator was implanted (PRIZM DR, Guidant, MN, USA). Genetic screening 
was not performed at the time of writing this report.
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Figure 1. Left Panel: 24-Hour Holter monitoring. During physical activity, BVT is precipitated by ventricular 
bigeminy  degenerating  into  polymorphic  ventricular  tachycardia  and  ventricular  fibrillation.  Right  Panel:  
amplification of a segment of the 24-hour Holter monitoring depicting alternating QRS complex morphologies  
with  different  polarities,  characteristic  features  of  BVT.                                  
This tachycardia suddenly degenerated into self-limiting polymorphic ventricular tachycardia 
and ventricular  fibrillation (Figure 1,  left  panel),  and normal  sinus rhythm resumed upon 
spontaneous cessation of ventricular fibrillation. The resting 12-lead ECG was normal after 
the event. (Figure 2)
During  a  ten  year  follow-up,  the  patient  presented  with  three  episodes  of  polymorphic 
ventricular tachycardia requiring ICD shocks. Propranolol dose was increased (160 mg/day) 
and the patient  remained asymptomatic  for  the last  two years.                                 
                                                                                                                         
CPVT is a rare but highly malignant (syncope or sudden cardiac death) genetic disease related 
to the mutation of cardiac ryanodine receptor gene (RYR2) or calsequestrin 2 gene (CASQ2), 
leading to an increase  in intracellular  Ca++ concentration,  resulting in arrhythmia due to a 
cascade of delayed after depolarization and triggered activity [3-6], and the four distinguishing 
features of CPVT have subsequently been described by Coumel et al [7]:  1) normal resting 
electrocardiogram; 2) exercise- or emotion-induced severe ventricular tachycardia; 3) a typical 
pattern  of  bidirectional  ventricular  tachycardia;  and  4)  a  structurally  normal  heart.     
BVT has  been described in  a  variety  of  clinical  settings  including digitalis  toxicity,  herbal 
aconite  poisoning,  hypokalemic  periodic  paralysis,  myocarditis,  coronary  artery  disease, 
metastatic cardiac tumors,  non-ischemic dilated cardiomyopathy, Anderson-Tawil syndrome, 
and at the same time, has been recognized as a hallmark of CPVT.[8]  It is usually triggered by 
exercise or emotional  stress.  It  can be precipitated by premature ventricular contractions or 
ventricular  bigeminy.  As  in  this  case,  it  can  degenerate  into  polymorphic  ventricular 
tachycardia and ventricular fibrillation.
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Figure 2. Normal resting 12-lead electrocardiogram
The treatment is directed to suppress adrenergic activity, therefore beta-blockers are the most 
important drug in the treatment of CPVT. Beta-blockers are effective for the acute phase and 
maintenance treatment. However, if symptoms recur, ICD should be considered. Flecainide is 
also part  of  the armamentarium to treat  this  infrequent  disease [9].                        
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